SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Auric Goldfinger's Short List
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: lindend who wrote (3098)9/15/1999 1:24:00 PM
From: Sir Auric Goldfinger  Read Replies (1) of 19428
 
The company has submitted an application for Evacet to be approved as a front-line therapy for metastatic breast cancer. There are three potential outcomes at this meeting.

1. Some type of recommendation (less than first-line therapy) at no better than 50/50. The estimate is that should this occur, LIPO's stock price could trade up from current levels.

2. Outright rejection as a first-line therapy. The estimate is that there is a 80% chance of this occurring and that the stock could trade significantly lower from current levels.

3. Recommendation as first-line therapy. The estimate is that there is a 20% chance of this occurring and that the stock could trade substantially higher from current levels.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News